Immunomedics, Inc. Awarded U.S. Patent for Internalizing Anti-CD74 Antibodies and Methods of Use

MORRIS PLAINS, N.J., Jan. 8, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that its patent application for "Internalizing anti-CD74 antibodies and methods of use" has been issued as U.S. patent no. 7,312,318. The patent covers the composition of matter for humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific antibodies that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is potentially useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.

Back to news